Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
3
×
deals
3
×
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
3
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
aduro biotech
biogen
cancer immunotherapy
diagnostics
drug prices
gilead sciences
What
bio
drug
3
×
roundup
companies
price
acquisitions
alzheimer’s
approval
biggest
biogen’s
biopharmaceutical
build
buy
ceo
company’s
convo
daniel
debut
different
dyne’s
earlier
fail
failures
gene
gilead
increases
latest
littered
microbiome
moves
nash
new
news
openly
o’day
pharmaceutical
pipeline
plan
prescription
prices
Language
unset
Current search:
cancer
×
drug
×
deals
×
novartis
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More